Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Axogen Inc (AXGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Axogen Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.77 (market cap $39.89B), while Axogen Inc trades at $40.3 (market cap $2.16B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 18.5× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AXGN | |
|---|---|---|
Market Cap | $39.89B | $2.16B |
Sector | Health | Technology |
52-Week High | $491.22 | $46.19 |
52-Week Low | $278.09 | $11.28 |
Enterprise Value | $38.15B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AXGN trades at $40.58, down 6.97% today, with neutral technical signals and mixed earnings performance. The company maintains strong gross margins of 75.01% but reported a net loss of $15.70 million in 2025. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $47.60 consensus price target, representing 17% upside potential from current levels.
While AXGN shows promising revenue growth and institutional support, persistent net losses and recent earnings misses create execution risk. The stock's valuation appears stretched with a P/S ratio of 8.12 despite negative profitability metrics. Positive reimbursement developments and nerve repair market expansion provide growth catalysts if the company can achieve sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
